Deprecated: Function set_magic_quotes_runtime() is deprecated in /web/1/manoa.hawaii.edu/chem/textpattern/lib/txplib_db.php on line 14 UH Manoa Chemistry: Stephen Margosiak

Stephen Margosiak

Contact

Department of Chemistry
University of Hawai’i at Manoa
2545 McCarthy Mall
Honolulu, HI 96822-2275

Phone: (808) 956-3207
Fax: (808) 956-5908
Email: Stephen Margosiak
Office: Bilger 245B

Educational Background

Postdoctoral Training (BioChemistry/Transient State Kinetics), 1990-1992 St. Jude Children’s Research Hospital, Memphis, TN.
Ph.D. (BioChemistry/Chemistry), New Mexico State University, Las Cruces, NM. 1990
M.S. (BioChemistry/Chemistry), New Mexico State University, Las Cruces, NM. 1988
B.A. (BioChemistry), American International College, Springfield, MA. 1984

Experience

Dr. Margosiak earned his Ph.D. In Chemistry/Biochemistry in 1990 from New Mexico State University, followed by a post-doctoral appointment at St Jude Children’s Research Hospital in the department of Molecular Pharmacology. Since that time Dr. Margosiak has pursued his career in the private sector working within the Biotech and Pharmaceutical industries.

Dr. Margosiak has extensive experience in enzymology, protein crystallography, and small molecule drug discovery and has a publication record indicating diverse drug discovery experience in various therapeutic areas such as cancer and infectious diseases. Dr. Margosiak, while at Agouron/Pfizer, was lead biochemist on a variety of cancer and anti-viral programs and served as group leader of the BioChemistry group. These research activates led to multiple NDAs with the FDA and ultimately to the marketing approval of Viracept™ for the treatment of HIV infections. Dr. Margosiak served as lead biochemist on projects leading to other clinical candidates reaching Phase III clinical trials such as Thymitaq™, Prinomastat, and Pelitrexol for cancer chemotherapy. As director of protein chemistry at Quorex pharmaceuticals, Dr. Margosiak was a key player in driving the success of anti-bacterial programs leading to acquisition of Quorex by Pfizer Pharmaceuticals. The most recent research activity centered around anti-viral drug discovery and the development of countermeasures to Bio-terrorism.